Wave Life Sciences Moved $233 Million Into Securities As A GSK Milestone Lifted Revenue
A $12.0 million GSK payment, still owed, drove third-quarter revenue to $13.2 million while cash and equivalents fell to $197.3 million.
Wave Life Sciences, a clinical-stage biotech that develops RNA medicines, reported third-quarter revenue of $13.2 million, of which $12.0 million is a GSK milestone it has yet to collect, according to its 10-Q filed Tuesday. Over nine months the company shifted its cash into bonds: cash and equivalents fell to $197.3 million from $602.1 million at year-end, while marketable securities rose to $233.4 million from zero.
A milestone, not cash
The $12.0 million came after GSK picked a GalNAc-siRNA candidate in September to move into its own pipeline. It sits in accounts receivable, and Wave said in its earnings release it expects to receive it in the fourth quarter.
The quarter's revenue compares with $7.6 million a year earlier. For the nine months, revenue was $53.7 million against $25.5 million, helped by $35.9 million of deferred revenue recognized when the alpha-1 antitrypsin license to GSK ended, plus the milestone.
Deferred revenue, a cushion of cash already received from GSK but not yet booked as revenue, fell to $21.4 million from $52.2 million at December 31. The nine-month decline of $30.8 million weighed on operating cash flow.
Where the cash went
Wave held $431.0 million in cash, equivalents and marketable securities at September 30, which excludes the $12 million GSK payment. It says that is enough to fund operations for at least twelve months, and the release puts the runway into the third quarter of 2028. Wave made no sales under its $250.0 million at-the-market stock program in the quarter or the nine months.
Investing activities used $234.8 million over nine months, mostly purchases of marketable securities. Operating activities used $173.3 million.
The net loss was $61.9 million in the quarter, versus $53.9 million a year earlier, and $157.4 million for nine months. Research and development spending rose to $53.8 million from $45.9 million, and general and administrative expense to $25.4 million from $18.1 million.
Pipeline and a Delaware move
Wave's lead programs are WVE-007 for obesity, WVE-006 for alpha-1 antitrypsin deficiency, a rare inherited disorder that damages the lungs and liver, and WVE-008 for a genetic liver disease. It uses its PRISM platform to design the drugs.
In October the company announced alignment with the FDA on a registrational path for WVE-006. On August 7, a reorganization made a Delaware company the parent of the group, exchanging Singapore shares one for one.
The company's market value was about $633 million in Tuesday morning data.
Wave expects to share 600 mg data for WVE-007 and WVE-006 and to file its WVE-008 trial application in the fourth quarter, and plans a virtual Research Day on November 4.
Sources
- 10-Q Filing — Wave Life Sciences (WVE) — SEC EDGAR
- 10-Q Filing — Wave Life Sciences (WVE), Q2 FY2026 filed 2026-07-30 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, d120442dex991.htm) — Wave Life Sciences, filed 2026-10-27 — SEC EDGAR
- Wave Life Sciences: Q3 Earnings Snapshot | wusa9.com — Associated Press
- Wave Life Sciences Reports Third Quarter 2026 Financial — globenewswire.com